Format

Send to

Choose Destination
J Clin Pharmacol. 2016 Apr;56(4):408-13. doi: 10.1002/jcph.605. Epub 2015 Oct 8.

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.

Author information

1
Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan.
2
P-One Clinic, Keikokai Medical Corporation, Hachioji, Tokyo, Japan.
3
Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara, Kanagawa, Japan.
4
Division of Hematology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.

Abstract

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy volunteers, including 6 individuals in each CYP2C19 genotype (extensive metabolizers [EMs], intermediate metabolizers [IMs], and poor metabolizers [PMs]), received a single oral dose of 3 mg tacrolimus alone or in combination with 200 mg voriconazole twice daily at steady state. When tacrolimus was coadministered with voriconazole, a significant increase in area under its concentration-time curve (AUC0-24 ) was observed for all genotypes. AUC0-12 of voriconazole in IMs and PMs were significantly higher than that in EMs (P < .05 and P < .01, respectively). Consequently, AUC0-24 of tacrolimus in combination with voriconazole in IMs and PMs were also significantly higher than that in EMs (P < .05). These results demonstrate that CYP2C19 genotypes influenced the exposure of tacrolimus when coadministered with voriconazole, although tacrolimus is mainly metabolized by CYP3A.

KEYWORDS:

CYP2C19 polymorphism; CYP3A; drug interaction; tacrolimus; voriconazole

PMID:
26239045
PMCID:
PMC5057355
DOI:
10.1002/jcph.605
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center